MyVisionTest News Archive

Displaying news items tagged with dosing strategy (More tags »)
SELECT PAGE
First <<  1 2 3   >> Last

CATT trial logo
Jan 15, 2012
The long-awaited primary outcome of the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) study was that patients receiving either monthly Avastin (bevacizumab) or monthly Lucentis (ranibizumab) had equivalent visual acuity at 1 year. For the majority of clinicians who already preferentially used Avastin for age-related...

Full Article


Lucentis
Mar 28, 2011
While visual improvement is frequently achieved following the almost universally accepted monthly injection for 3 months initiation phase of Lucentis (ranibizumab), the only proven treatment regime to maintain the initial gain in visual acuity (VA) is the monthly injection of Lucentis. The advantages of this regimen include simplicity and the...

Full Article


Lucentis
Feb 27, 2011
There is less improvement of vision with as-needed intravitreal Lucentis (ranibizumab) than with monthly injections, according to a new study. Ocular anti-VEGF therapy has presented a major breakthrough in the care of patients with exudative AMD, giving rise to a wide array of therapeutic strategies among retinal specialists, with no consensus...

Full Article


Avastin
Feb 26, 2011
Utilizing a treat-and-extend treatment regimen for Avastin (bevacizumab) and Lucentis (ranibizumab) therapy proved visually efficacious as well as time- and cost-efficient among patients with neovascular age-related macular degeneration (AMD), a speaker said at the Macula 2011 meeting. While visual outcomes and recurrence rates were similar for...

Full Article


Lucentis
Jan 21, 2011
It would have been nice if patients who take monthly intravitreal injections of ranibizumab (Lucentis) could have dropped back to quarterly injections instead, but a new study shows a less frequent schedule is also less effective at reducing vision loss. Everyone enrolled in the EXCITE study had age-related macular degeneration with subfoveal...

Full Article


Intravitreal injection
Jan 20, 2011
Ocular anti-VEGF therapy has presented a major breakthrough in the care of patients with exudative AMD, giving rise to a wide array of therapeutic strategies among ophthalmologists, with no consensus on optimal practices. As an alternative to the strict regimen of monthly intravitreal injection used in the protocols of the pivotal ranibizumab...

Full Article


Intravitreal injection
Jan 16, 2011
Researchers studied choroidal neovascularization recurrence interval times in patients with neovascular age-related macular degeneration (AMD) after intravitreal anti-VEGF therapy. Individualized anti-VEGF dosing that aims to avoid recurrent CNV activity as well as additionally to further reduce the number of injections and visits would aim to...

Full Article


Intravitreal injection
Oct 17, 2010
Intravitreal Avastin (bevacizumab, IVB) is safe and effective for patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) over a 24-month follow-up period, according to a new study. In 2006, the United States Food and Drug Administration approved the use of Lucentis (ranibizumab) for the...

Full Article


Age-related macular degeneration
Sep 20, 2010
A drop in visual acuity, persistent or recurrent fluid on ocular coherence tomography, new hemorrhage or distortion are all "markers" that can assist in monitoring the effectiveness of Lucentis treatment in age-related macular degeneration (AMD) cases, a clinician said here. Monitoring Lucentis (ranibizumab) therapy in AMD treatment can be...

Full Article


Lucentis
Aug 29, 2010
Lucentis was safe and effective with quarterly (and then monthly) dosing during the 2-year Phase IIIb PIER study of subjects with neovascular age-related macular degeneration (AMD), accordingto a new report from the study. Lucentis provided significant visual acuity (VA) benefit in patients with AMD-related CNV compared with sham injection....

Full Article


SELECT PAGE
First <<  1 2 3   >> Last
Most Popular
Less - past - More